IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i9p5585-d808457.html
   My bibliography  Save this article

Persistence of Adverse Drug Reaction-Related Hospitalization Risk Following Discharge

Author

Listed:
  • Olive Schmid

    (School of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7001, Australia)

  • Bonnie Bereznicki

    (Tasmanian School of Medicine, University of Tasmania, Hobart, TAS 7000, Australia)

  • Gregory Mark Peterson

    (School of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7001, Australia)

  • Jim Stankovich

    (School of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7001, Australia)

  • Luke Bereznicki

    (School of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7001, Australia)

Abstract

This retrospective cohort study analyzed the administrative hospital records of 91,500 patients with the aim of assessing adverse drug reaction (ADR)-related hospital admission risk after discharge from ADR and non-ADR-related admission. Patients aged ≥18 years with an acute admission to public hospitals in Tasmania, Australia between 2011 and 2015 were followed until May 2017. The index admissions ( n = 91,550) were stratified based on whether they were ADR-related ( n = 2843, 3.1%) or non-ADR-related ( n = 88,707, 96.9%). Survival analysis assessed the post-index ADR-related admission risk using (1) the full dataset, and (2) a matched subset of patients using a propensity score analysis. Logistic regression was used to identify the risk factors for ADR-related admissions within 90 days of post-index discharge. The patients with an ADR-related index admission were almost five times more likely to experience another ADR-related admission within 90 days ( p < 0.001). An increased risk persisted for at least 5 years ( p < 0.001), which was substantially longer than previously reported. From the matched subset of patients, the risk of ADR-related admission within 90 and 365 days more than doubled in the patients with an ADR-related index admission ( p < 0.0001). These admissions were often attributed to the same drug class as the patients’ index ADR-related admission. Cancer was a major risk factor for ADR-related re-hospitalization within 90 days; other factors included heart failure and increasing age.

Suggested Citation

  • Olive Schmid & Bonnie Bereznicki & Gregory Mark Peterson & Jim Stankovich & Luke Bereznicki, 2022. "Persistence of Adverse Drug Reaction-Related Hospitalization Risk Following Discharge," IJERPH, MDPI, vol. 19(9), pages 1-12, May.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:9:p:5585-:d:808457
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/9/5585/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/9/5585/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Katja M Hakkarainen & Khadidja Hedna & Max Petzold & Staffan Hägg, 2012. "Percentage of Patients with Preventable Adverse Drug Reactions and Preventability of Adverse Drug Reactions – A Meta-Analysis," PLOS ONE, Public Library of Science, vol. 7(3), pages 1-9, March.
    2. Nibu Parameswaran Nair & Leanne Chalmers & Bonnie J. Bereznicki & Colin Curtain & Gregory M. Peterson & Michael Connolly & Luke R. Bereznicki, 2017. "Adverse Drug Reaction-Related Hospitalizations in Elderly Australians: A Prospective Cross-Sectional Study in Two Tasmanian Hospitals," Drug Safety, Springer, vol. 40(7), pages 597-606, July.
    3. Fatema A. Alqenae & Douglas Steinke & Richard N. Keers, 2020. "Prevalence and Nature of Medication Errors and Medication-Related Harm Following Discharge from Hospital to Community Settings: A Systematic Review," Drug Safety, Springer, vol. 43(6), pages 517-537, June.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Akshaya Srikanth Bhagavathula & Asim Ahmed Elnour & Shazia Qasim Jamshed & Abdulla Shehab, 2016. "Health Professionals' Knowledge, Attitudes and Practices about Pharmacovigilance in India: A Systematic Review and Meta-Analysis," PLOS ONE, Public Library of Science, vol. 11(3), pages 1-15, March.
    2. Mona Kargar & Alireza Ahmadvand & Kheirollah Gholami, 2018. "Comment on: “Adverse Drug Reaction-Related Hospitalizations in Elderly Australians: A Prospective Cross-Sectional Study in Two Tasmanian Hospitals”," Drug Safety, Springer, vol. 41(3), pages 321-322, March.
    3. Chirn-Bin Chang & Hsiu-Yun Lai & Shu-Yu Yang & Ru-Shu Wu & Hsing-Cheng Liu & Hsiu-Ying Hsu & Shinn-Jang Hwang & Ding-Cheng Chan, 2014. "Patient- and Clinic Visit-Related Factors Associated with Potentially Inappropriate Medication Use among Older Home Healthcare Service Recipients," PLOS ONE, Public Library of Science, vol. 9(4), pages 1-7, April.
    4. Josephine Henry Basil & Chandini Menon Premakumar & Adliah Mhd Ali & Nurul Ain Mohd Tahir & Noraida Mohamed Shah, 2022. "Prevalence, Causes and Severity of Medication Administration Errors in the Neonatal Intensive Care Unit: A Systematic Review and Meta-Analysis," Drug Safety, Springer, vol. 45(12), pages 1457-1476, December.
    5. Sun-Joo Jang & Haeyoung Lee & Youn-Jung Son, 2021. "Perceptions of Patient Safety Culture and Medication Error Reporting among Early- and Mid-Career Female Nurses in South Korea," IJERPH, MDPI, vol. 18(9), pages 1-11, May.
    6. Renly Lim & Lisa M. Kalisch Ellett & Susan Semple & Elizabeth E. Roughead, 2022. "The Extent of Medication-Related Hospital Admissions in Australia: A Review from 1988 to 2021," Drug Safety, Springer, vol. 45(3), pages 249-257, March.
    7. Alexandre R. Marra & Abdullah Algwizani & Mohammed Alzunitan & Theresa M. H. Brennan & Michael B. Edmond, 2020. "Descriptive Epidemiology of Safety Events at an Academic Medical Center," IJERPH, MDPI, vol. 17(1), pages 1-11, January.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:9:p:5585-:d:808457. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.